The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth

The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth

It is well established that Cholangiocarcioma (CCA) drug resistance plays a crucial role in the spread and survival of cancer cells. The major enzyme in the nicotinamide-adenine dinucleotide (NAD+)-mediated pathways, nicotinamide phosphoribosyltransferase (NAMPT), is essential for cancer cell surviv...

Full description

Bibliographic Details
Main Authors: Kishor Pant, Seth Richard, Estanislao Peixoto, Jun Yin, Davis M. Seelig, Pietro Carotenuto, Massimiliano Salati, Brunella Franco, Lewis R. Roberts, Sergio A. Gradilone
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cells
Subjects:
NAMPT
NAD
FK866
Cholangiocarcinoma
cisplatin
Online Access:https://www.mdpi.com/2073-4409/12/5/775

Internet

https://www.mdpi.com/2073-4409/12/5/775

Similar Items